Table 3.

European LeukemiaNet (ELN) and National Comprehensive Cancer Network (NCCN) Recommendations For Monitoring and Evaluation Timepoints in Patients With Chronic Myeloid Leukemia

	ELN guidelines		NCCN guidelines
	Assessment	Optimal Response	Assessment	Optimal Response
3 months	Hematology qRT–PCRa Cytogeneticsb	CHR and at least mCyR	Hematology qRT–PCR	CHR
6 months	qRT–PCRa Cytogeneticsb,c	At least PCyR	qRT–PCR Cytogeneticse,f	CCyR or PCyR
12 months	qRT–PCRa Cytogeneticsb,c	CCyR	qRT–PCR Cytogeneticse,g	CCyR
18 months	qRT–PCR Cytogeneticsb,c	MMR	qRT–PCR Cytogeneticse	CCyR

CHR = complete hematologic response; mCyR = minor cytogenetic response; CCyR = complete cytogenetic response; MMR = major molecular response; PCyR = partial cytogenetic response; qRT–PCR = quantitative reverse transcription polymerase chain reaction.

^aRepeat every 3 months until MMR is confirmed, then every 6 months.

^bPerform with chromosome banding analysis of marrow cell metaphases.

^cRepeat every 6 months until a CCyR is confirmed, then every 12 months if no regular monitoring and always when myelodysplastic features, suboptimal response, or failure occurs.

^dRepeat every 3 months. If a CCyR is achieved, repeat every 3 months for 3 years, then every 3 to 6 months.

^ePerform on bone marrow.

^fIf no CCyR at 6 months, repeat cytogenetics at 12 months.

^gIf no CCyR at 12 months, repeat cytogenetics at 18 months.

Adapted with permission from the NCCN Guidelines for Chronic Myelogenous Leukemia.¹³

Additional data from Baccarani M, et al. Best Pract Res Clin Haematol 2009;22(3):331–341.¹²